Fingolimod Clinical Trials

4 actively recruiting trials across 1 location

No change since June 2026

Also known as: FTY720

Pipeline

Phase 3: 1Phase 4: 2Phase 2/3: 1

Top Sponsors

TG Therapeutics, Inc.1
Novartis Pharmaceuticals1
General Hospital of Shenyang Military Region1
Bristol-Myers Squibb1

Indications

Multiple Sclerosis3
Relapsing Multiple Sclerosis1
Multiple Sclerosis, Relapsing-Remitting1
Diabetes1
Diabetes Mellitus, Type 21

Other3 trials

Fingolimod for Type 2 Diabetes Mellitus

Phase 4

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Phase 4

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Phase 2/3

Loma Linda, California1 trial

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Local Institution - 0114

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.